IRB #

IRB00011845

Title

A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-LI Antibody) Compared with A Platinum Agent (Cisplatin or Carboplatin) in Combination with either Pemetrexed or Gemcitabine for PD-L1-Selected, Chemotherapy-Naïve Patients Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer

Principal Investigator

Jeremy Cetnar

Study Purpose

The purpose is to evaluate the efficacy of the study drug compared to carboplatin or cisplatin in combination with either pemetrexed (non-squamous disease) or gemcitabine (squamous disease) in patients who have not received chemotherapy with stage IV non-squamous or squamous Non-Small Cell Lung Cancer (NSCLC) and to evaluate their tumor response while taking part in the study.

Medical Condition(s)

Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) Stage IV

Eligibility Criteria

Females and males age 18 and older
ECOG of 0-1
No prior treatment for Stage IV NSCLC
Measurable disease

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Treated until their cancer or quality of life progresses/gets worse

Minors Included

No

Contact

Knight Information Line - trials@ohsu.edu or 503-494-1080

Sponsor

F. Hoffmann-La Roche Ltd

Recruitment End

06/15/2020

Compensation Provided

No


Go Back